NO20090158L - Composition comprising naproxen nanoparticles and controlled release hydrocarbon - Google Patents
Composition comprising naproxen nanoparticles and controlled release hydrocarbonInfo
- Publication number
- NO20090158L NO20090158L NO20090158A NO20090158A NO20090158L NO 20090158 L NO20090158 L NO 20090158L NO 20090158 A NO20090158 A NO 20090158A NO 20090158 A NO20090158 A NO 20090158A NO 20090158 L NO20090158 L NO 20090158L
- Authority
- NO
- Norway
- Prior art keywords
- composition
- hydrocodone
- combination
- controlled release
- bimodal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Den foreliggende oppfinnelsen gjelder sammensetninger som omfatter en nanopartikulær naproksensammensetning i kombinasjon med en multipartikulær hydrokodonsammensetning for modifisert frigivelse som etter administrering til en pasient tilfører et hydrokodon på en bimodal eller multimodal måte. Den multipartikulære sammensetningen for modifisert frigivelse omfatter en første bestanddel og minst én påfølgende bestanddel hvor den første bestanddelen omfatter en første populasjon av hydrokodonholdige partikler og den minst ene påfølgende bestanddelen omfatter en andre populasjon av hydrokodonholdige partikler, hvori kombinasjonen av bestanddelene gir en bimodal eller multimodal frigivelsesprofil. Oppfinnelsen gjelder også en fast oral doseringsform som omfatter en slik kombinasjonssammensetning.The present invention relates to compositions comprising a nanoparticulate naproxen composition in combination with a modified release multiparticulate hydrocodone composition which, after administration to a patient, supplies a hydrocodone in a bimodal or multimodal manner. The modified release multiparticulate composition comprises a first component and at least one subsequent component wherein the first component comprises a first population of hydrocodone-containing particles and the at least one subsequent component comprises a second population of hydrocodone-containing particles, wherein the combination of the components provides a bimodal or multimodal release profile. . The invention also relates to a solid oral dosage form comprising such a combination composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81588506P | 2006-06-23 | 2006-06-23 | |
PCT/US2007/072052 WO2007150074A2 (en) | 2006-06-23 | 2007-06-25 | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090158L true NO20090158L (en) | 2009-03-20 |
Family
ID=38834446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090158A NO20090158L (en) | 2006-06-23 | 2009-01-12 | Composition comprising naproxen nanoparticles and controlled release hydrocarbon |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2032137A2 (en) |
JP (1) | JP2009541359A (en) |
KR (1) | KR20090024284A (en) |
CN (1) | CN101484170A (en) |
AU (1) | AU2007260821B2 (en) |
BR (1) | BRPI0713447A2 (en) |
CA (1) | CA2660649A1 (en) |
IL (1) | IL196065A0 (en) |
MX (1) | MX2008016223A (en) |
NO (1) | NO20090158L (en) |
WO (1) | WO2007150074A2 (en) |
ZA (1) | ZA200810221B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
ES2360102T3 (en) | 2003-03-26 | 2011-05-31 | Egalet A/S | SYSTEM FOR CONTROLLED RELEASE OF MORPHINE. |
NZ580972A (en) | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
KR101572336B1 (en) | 2010-12-22 | 2015-11-26 | 퍼듀 퍼머 엘피 | Encased tamper resistant controlled release dosage forms |
CN103327969A (en) | 2010-12-23 | 2013-09-25 | 普渡制药公司 | Tamper resistant solid oral dosage forms |
KR101794032B1 (en) | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | Method for preparing nanoparticles |
WO2014006004A1 (en) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
EA201500742A1 (en) | 2013-02-05 | 2015-12-30 | Пердью Фарма Л.П. | PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
CN112500694B (en) * | 2020-12-04 | 2022-03-29 | 东莞威赢高尔夫用品有限公司 | Electronic equipment veneer material and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
RU2236847C2 (en) * | 1998-11-02 | 2004-09-27 | Илан Корпорейшн, Плк. | Composition as multiple particles with modified release |
ATE487470T1 (en) * | 2002-09-11 | 2010-11-15 | Elan Pharma Int Ltd | GEL-STABILIZED ACTIVE COMPOSITIONS IN NANOPARTICLE SIZE |
-
2007
- 2007-06-25 CN CNA2007800236169A patent/CN101484170A/en active Pending
- 2007-06-25 JP JP2009516756A patent/JP2009541359A/en active Pending
- 2007-06-25 CA CA002660649A patent/CA2660649A1/en not_active Abandoned
- 2007-06-25 KR KR1020097001439A patent/KR20090024284A/en not_active Application Discontinuation
- 2007-06-25 AU AU2007260821A patent/AU2007260821B2/en not_active Expired - Fee Related
- 2007-06-25 MX MX2008016223A patent/MX2008016223A/en not_active Application Discontinuation
- 2007-06-25 BR BRPI0713447-9A patent/BRPI0713447A2/en not_active IP Right Cessation
- 2007-06-25 EP EP07799011A patent/EP2032137A2/en not_active Withdrawn
- 2007-06-25 WO PCT/US2007/072052 patent/WO2007150074A2/en active Application Filing
-
2008
- 2008-12-02 ZA ZA200810221A patent/ZA200810221B/en unknown
- 2008-12-18 IL IL196065A patent/IL196065A0/en unknown
-
2009
- 2009-01-12 NO NO20090158A patent/NO20090158L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL196065A0 (en) | 2009-09-01 |
WO2007150074A3 (en) | 2008-04-10 |
EP2032137A2 (en) | 2009-03-11 |
AU2007260821A1 (en) | 2007-12-27 |
AU2007260821B2 (en) | 2012-06-21 |
BRPI0713447A2 (en) | 2012-03-13 |
WO2007150074A2 (en) | 2007-12-27 |
ZA200810221B (en) | 2009-11-25 |
KR20090024284A (en) | 2009-03-06 |
CA2660649A1 (en) | 2007-12-27 |
MX2008016223A (en) | 2009-01-19 |
CN101484170A (en) | 2009-07-15 |
JP2009541359A (en) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090158L (en) | Composition comprising naproxen nanoparticles and controlled release hydrocarbon | |
NO20090119L (en) | Composition comprising controlled release nanoparticulated meloxicam and hydrocodone | |
CY1125077T1 (en) | TREATMENT OF VITAMIN D DEFICIENCY AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3 | |
BR112012030552A2 (en) | immunogenic composition | |
CL2009000171A1 (en) | Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression. | |
CL2007003604A1 (en) | Pharmaceutical composition for oral administration comprising the amorphous 17-aminogeldanamycin compound; and its use in the treatment of cancer. | |
WO2010037059A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
WO2010003127A3 (en) | Antagonists of prostaglandin d2 receptors | |
NO20073802L (en) | Leuprolide acetate and acetylcholine sterase inhibitor or NMDA receptor antagonists for the treatment of Alzheimer's disease | |
WO2010039977A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
CL2007003299A1 (en) | COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE HEPATITIS C VIRUS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C. | |
DE602007006961D1 (en) | CGRP RECEPTOR ANTAGONISTS | |
CL2011001131A1 (en) | Use of a formulation that serves to prepare a drug for an injection, which minimizes inflammation at the site of injection of an antibody, and where the formulation comprises a 2h7 antibody and variants of the antibody and polyvinylpyrrolidone (pvp) | |
WO2009145989A3 (en) | Aminoalkylphenyl antagonists of prostaglandin d2 receptors | |
UA96308C2 (en) | Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof | |
GB2460597A (en) | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | |
CL2007002658A1 (en) | COMPOUNDS DERIVED FROM PURINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF AN INFLAMMATORY OR OBSTRUCTIVE DISEASE OF THE RESPIRATORY ROADS. | |
WO2009140642A3 (en) | Tricyclic antagonists of prostaglandin d2 receptors | |
DK1748756T3 (en) | Compositions comprising molecularly dispersed drospirenone | |
WO2007095091A3 (en) | Oral delivery of therapeutic agents using tight junction agonists | |
ECSP099634A (en) | USED PIRIDAZINONE DERIVATIVES AS INHIBITORS OF GLUCANO SINTASA | |
EA201001253A1 (en) | N, N-DESIGNED AMINOALKYLBIPHENYLES AS ANTAGONISTS OF PROSTAGLANDIN RECEPTORS D | |
WO2010042652A3 (en) | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors | |
CL2009000281A1 (en) | Compounds derived from 5,6-dihydro-pyrrolo- [2,1-a] -isoquinolines and pyrrolo- [2,1-a] -isoquinolines; pharmaceutical composition comprising said compounds; and use for the treatment of fertility disorders. | |
WO2010116282A8 (en) | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |